Drugs / SKB500
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06736327 | Dec 2024 → Jul 2027 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07700667 | Jul 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07296809 | Jan 2026 → Dec 2028 expected | small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Results Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026 kelun-biotech.com ↗
Antitumor activities were observed across multiple solid tumor types, including SCLC, ESCC, HNSCC, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma (NPC). |
| 2024-12-04 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech’s ADC Innovator SKB500 for Advanced Solid Tumors Receives A Clinical Trial Notice kelun-biotech.com ↗
On Dec.4, the innovative drug SKB500 developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) received a clinical trial notice approving the investigational new drug application from the Center for Drug Evaluation of the National Medical Products Administration (NMPA). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026 kelun-biotech.com ↗ |
| 2024-12-04 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech’s ADC Innovator SKB500 for Advanced Solid Tumors Receives A Clinical Trial Notice kelun-biotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736327 ↗ |
| Route | Intravenous | “The administration route of SKB500 is intravenous infusion” NCT06736327 ↗ |